PMID- 35078396
OWN - NLM
STAT- MEDLINE
DCOM- 20220916
LR  - 20221012
IS  - 1875-5704 (Electronic)
IS  - 1567-2018 (Linking)
VI  - 19
IP  - 10
DP  - 2022
TI  - Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A 
      Review.
PG  - 1012-1033
LID - 10.2174/1567201819666220117102658 [doi]
AB  - Cancer is one of the leading causes of mortality worldwide. Although 
      chemotherapeutic agents have been effectively designed to increase the survival 
      rates of some patients, the designed chemotherapeutic agents necessarily deliver 
      toxic chemotherapeutic drugs to healthy tissues, resulting in serious side 
      effects. Cancer cells can often acquire drug resistance after repeatedly 
      administering current chemotherapeutic agents, restricting their efficacy. Given 
      such obstacles, investigators have attempted to distribute chemotherapeutic 
      agents using targeted drug delivery systems (DDSs), especially 
      nanotechnology-based DDSs. The lipid-based nanoparticles (LBNPs) are a large and 
      complex class of substances utilized to manage various diseases, especially 
      cancers. Liposomes seem to be the most frequently employed LBNPs, owing to their 
      high biocompatibility, bioactivity, stability, and flexibility. Solid lipid NPs 
      and non-structured lipid carriers have lately received a lot of interest. In 
      addition, several reports focused on novel therapies via LBNPs to manage various 
      forms of cancer. In the present research, the latest improvements in applying 
      LBNPs have been shown to deliver different therapeutic agents to cancerous cells 
      and be a quite successful candidate in cancer therapy.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Khodaverdi, Hamed
AU  - Khodaverdi H
AD  - National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
FAU - Zeini, Maryam Shokrian
AU  - Zeini MS
AD  - Department of Pharmacology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
AD  - Experimental Medicine Research Center, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Moghaddam, Mehrdad Moosazadeh
AU  - Moghaddam MM
AD  - Applied Biotechnology Research Center, Baqiyatallah University of Medical 
      Sciences, Tehran, Iran.
FAU - Vazifedust, Soheil
AU  - Vazifedust S
AD  - Faculty of Veterinary Medicine, University of Urmia, Urmia, Iran.
FAU - Akbariqomi, Mostafa
AU  - Akbariqomi M
AD  - Applied Biotechnology Research Center, Baqiyatallah University of Medical 
      Sciences, Tehran, Iran.
FAU - Tebyaniyan, Hamid
AU  - Tebyaniyan H
AD  - Islamic Azad University, Science and Research Branch, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Deliv
JT  - Current drug delivery
JID - 101208455
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Lipids)
RN  - 0 (Liposomes)
SB  - IM
MH  - *Antineoplastic Agents
MH  - Drug Carriers/therapeutic use
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Lipids
MH  - Liposomes
MH  - *Nanoparticles
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - Cancer
OT  - drug
OT  - lipid-based carriers
OT  - nanoparticle
OT  - non-structured lipid carriers
OT  - targeted delivery
EDAT- 2022/01/27 06:00
MHDA- 2022/09/17 06:00
CRDT- 2022/01/26 05:25
PHST- 2021/09/20 00:00 [received]
PHST- 2021/11/01 00:00 [revised]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2022/01/27 06:00 [pubmed]
PHST- 2022/09/17 06:00 [medline]
PHST- 2022/01/26 05:25 [entrez]
AID - CDD-EPUB-120205 [pii]
AID - 10.2174/1567201819666220117102658 [doi]
PST - ppublish
SO  - Curr Drug Deliv. 2022;19(10):1012-1033. doi: 10.2174/1567201819666220117102658.